	US 12,213,977 B2
	Methods and compositions for treating melanoma
Thomas G. Graeber, Los Angeles, CA (US); Jennifer Tsoi, Los Angeles, CA (US); Antoni Ribas, Los Angeles, CA (US); Lidia Robert, Los Angeles, CA (US); and Nicolaos Palaskas, Los Angeles, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US)
Appl. No. 16/625,075
Filed by THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US)
PCT Filed Jun. 27, 2018, PCT No. PCT/US2018/039822 § 371(c)(1), (2) Date Dec. 20, 2019, PCT Pub. No. WO2019/006005, PCT Pub. Date Jan. 3, 2019.
Claims priority of provisional application 62/650,051, filed on Mar. 29, 2018.
Claims priority of provisional application 62/525,969, filed on Jun. 28, 2017.
Prior Publication US 2020/0163966 A1, May 28, 2020
Int. Cl. A61K 31/517 (2006.01); A61K 31/437 (2006.01); A61K 35/17 (2015.01); A61K 45/06 (2006.01); C07K 16/28 (2006.01)

CPC A61K 31/517 (2013.01) [A61K 31/437 (2013.01); A61K 35/17 (2013.01); C07K 16/2818 (2013.01); A61K 45/06 (2013.01)]

12 Claims

1. A method for treating or preventing BRAF inhibitor resistance in a subject having dedifferentiated melanoma, the method comprising administering a GPX4 inhibitor and a BRAF inhibitor in parallel.